For instance, in treatment-naïve MTC, ORR was 73% for selpercatinib and 71% for pralsetinib; in pretreated MTC, ORR was 69 and 60%, respectively; and in RET fusion PTC, ORR was 79 and 89%, respectively (Wirth et al. 2020, Subbiah et al. 2021b). The gene discussed is RET; the disease is medullary thyroid gland carcinoma.